She also reported that the company will conduct another separate clinical study with the goal of collecting a variety of biomarker information from patients with dry eye disease in order to develop tailored treatments.
This tailored approach is important because of the wide diversity of symptoms. Flavio Mantelli, MD, PhD, explained the benefits of this approach.
“The effects of currently available treatments for chronic dry eye disease mostly address only inflammation and wear off soon after discontinuing therapy.” Said Dr. Mantelli, chief medical officer of Dompé.
The mechanism of action of NGF is well understood, he pointed out. He added that the research team hopes to utilize that mechanism to produce a new longer acting therapy that reduces the treatment burden, that includes rhNGF, for patients with dry eye disease.
Dr. Toyos went on to explain that because of the challenge of both diagnosing and managing dry eye, she is excited to investigate the potential of a treatment that may address the underlying tear production deficiency and the neuro-sensory abnormalities, which could result in a disease modifying therapy.
The primary study endpoint is the change from baseline in ocular surface tear wetting measured using the Schirmer I test. The secondary endpoints are the signs and symptoms of dry eye disease, including ocular surface staining, which is an objective measure of ocular surface integrity and health.
RELATED CONTENT: Nutrition a priority for dry eye patients
Melissa Toyos, MD
E: [email protected]
Dr. Toyos is an investigator in the trial. She has no other financial relationships to report.